Health care stocks were rising premarket Wednesday, with The Health Care Select Sector SPDR Fund (XLV) up 0.8% and the iShares Biotechnology ETF (IBB) 1.8% higher.
Keros Therapeutics (KROS) shares were down 25% after the company said it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."
NeoGenomics (NEO) stock was over 6% higher after the company said it expects 2025 total revenues in the range of $735 million to $745 million. Analysts surveyed by FactSet expect $727.8 million.
Context Therapeutics (CNTX) shares were more than 10% higher after the company said it has dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。